Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain.
Expert Opin Ther Targets
; 24(10): 1009-1028, 2020 10.
Article
en En
| MEDLINE
| ID: mdl-32746649
ABSTRACT
INTRODUCTION:
The sigma receptors are found abundantly in the central nervous system and are targets for the treatment of various diseases, including Alzheimer's (AD), Parkinson's (PD), Huntington's disease (HD), depression, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). However, for many of these diseases, other receptors and targets have been the focus of the most, such as acetylcholine esterase inhibitors in Alzheimer's and dopamine replacement in Parkinson's. The currently available drugs for these diseases have limited success resulting in the requirement of an alternative approach to their treatment. AREAS COVERED In this review, we discuss the potential role of the sigma receptors and their ligands as part of a multi receptor approach in the treatment of the diseases mentioned above. The literature reviewed was obtained through searches in databases, including PubMed, Web of Science, Google Scholar, and Scopus. EXPERT OPINION Given sigma receptor agonists provide neuroprotection along with other benefits such as potentiating the effects of other receptors, further development of multi-receptor targeting ligands, and or the development of multi-drug combinations to target multiple receptors may prove beneficial in the future treatment of degenerative diseases of the CNS, especially when coupled with better diagnostic techniques.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Encefalopatías
/
Receptores sigma
/
Terapia Molecular Dirigida
Límite:
Animals
/
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article